Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bifico + Chemotherapy in Advanced NSCLC
NCT03642548Phase 3Unknown
- Sponsor
- Shanghai Tenth People's Hospital
- Start
- Feb 2019
- Primary completion
- Mar 2024
- Modality
- Yeast Strains, Defined Consortia, Bacterial Strains
01
Overview
Phase 3, randomised, double-blind trial of bifidobacterium longum/lactobacillus acidophilus/enterococcus faecalis in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shanghai Tenth People's Hospital. Primary endpoints: Objective Response Rate at 14 months and Progression Free Survival at 6 months. Status: unknown.
02
Drugs
bifidobacterium longum/lactobacillus acidophilus/enterococcus faecalis
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03642548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03642548.